Lifeboat Foundation

With global corporate-venture-capital-backed (CVC) funding reaching $79 billion across 2,099 deals in the first half of 2,021 according to CB Insights, the chances are high that startups will find great opportunities with this growing investor set.

Entrepreneurs, however, are likely to discover that the investment process can be different for CVCs compared to private venture capital firms. While both types of investment firms tend to make decisions via an investment committee (IC), private VCs (inclusive of VCs with corporate backers that have an independent LPA structure) make up their ICs with firm partners and/or other venture-minded people.

But for CVCs investing off a corporate balance sheet, the IC can include corporate-minded people, such as the CEO or business unit leaders, who generally tend to be detached from the venture mindset and the requirements for operating in the VC world. As such, entrepreneurs will realize that a successful CVC investment decision tends to have different requirements compared to a private VC firm’s decision.

A solar farm in Spain has commissioned a series of iron-flow batteries to store excess energy. This could be the beginning of the end for lithium-ion.

Fixing breaks in genes with speed and perfection can be a matter of life and death for most organisms. Even the simplest changes in a sequence risk catastrophe, especially if the altered code is responsible for a critical function.

Over the past half a century, biologists have studied the mechanisms involved to piece together most of the major steps involved in making faithful repairs in DNA. Yet, one part of the process has remained frustratingly unclear.

By marking key enzymes and DNA with fluorescent tags and watching the repair process unfold in real-time in an Escherichia coli model, researchers from Uppsala University in Sweden have filled in missing details on how bacteria find the templates they rely on to keep genetic repairs error-free.

The automobile industry has recently been inclining towards electrical vehicles and governments are doing everything to support this transition. Tesla has been a pioneer and an example in this field. It has launched smart vehicles and maintained the standard. However, no, the company has a rival, and it might be a threat to Tesla’s models.

Lucid Motors is another automobile company making electric vehicles. It just earned a rating of 520 miles (837 km) from the Environmental Protection Agency for the firm’s model of Air Dream Edition. This makes the Lucid Air the longest-range EV the EPA has ever rated, according to a recent press release.

However, EPA has very specific and low context settings for trials. Hence, the speed and other specifications will perform differently in real road scenarios. This model is the longest-range production EV so far. The company’s CTO and CEO Peter Rawlinson has scored a win as the Air Dream Edition exceeds Tesla’s longest-range vehicle, the Model S Long Range Plus, by a staggering 100 miles (161 km).

Riz Virk, the author of the new book The Simulated Multiverse, talks with GamesBeat’s Dean Takahashi about sci-fi and reality.

HI! I am a news anchor and I have a passion for making videos and I love sharing parts of my experience with you, the viewer!

Your support for my channel means a lot. Thanks for watching and if you have any video ideas, shoot me an email, [email protected].

Continue reading “Ellie in Space and Warren Redlich reflect on BOCA CHICA” »

New #preprint from JAX’s Nadia Rosenthal and researchers at Rocky Mountain Laboratories: “Genetically diverse mouse models of SARS-CoV-2 infection recapitulate clinical variation and cytokine responses in COVID-19”

The preprint, which has yet to be peer reviewed, shows that mice with different genetic backgrounds exhibit highly variable responses to SARS-CoV-2 infection, mirroring the large differences in #COVID19 disease severity seen in humans:

Since the advent of the COVID-19 pandemic, tremendous progress has been made in developing effective vaccines against SARS-CoV-2, the coronavirus that causes COVID-19, and in treating ill patients. Nonetheless, much more needs to be learned about SARS-CoV-2 infectivity and COVID-19 progression to lessen the continuing threat of infection, as the recent emergence and rapid spread of the delta variant has emphasized.

Like many other living organisms, humans are born, survive, compete for resources, reach maturity, reproduce, take care of their young, sometimes the young of their young, continuously decline, and die. Evolution needs us for just two purposes – adapt and reproduce. But, unlike other species, humans are very conscious of their fate. Humans are very much aware that after reaching peak performance they will eventually grow old and die. We are very conscious of our fate after reaching peak performance – loss of function, frailty, and eventual loss of everything we worked so hard to earn.

We observe our parents, and other elderly around them, attend funerals, and understand that eventually we will get into this state. We are also very contempt with that fate as evolution made sure that. The more ambitious of us are trying to advance science, the rest seek refuge in religion, some in philosophy, some in accumulation of wealth, and some see the continuation of ourselves in our children. But despite the many technological advances transpiring in the laboratories all over the world, there is nothing we can do at this point to escape aging. There are diets, exercises, sleep, and supplements, but these provide very marginal benefits. We do not see 120+ old yoga and diet practitioners or marathon runners around. But these simple habits do help look younger longer. And many people that have very harmful habits like smoking but still diet and exercise to look younger.

Among thousands of the earliest survivors of COVID-19 in Wuhan, China, nearly half had at least one persistent symptom a full year after being released from the hospital, according to a new study published in JAMA Network Open.

The study followed up with 2,433 adult patients who had been hospitalized in one of two hospitals in Wuhan early on in the pandemic. Most had nonsevere cases, but a small number had severe COVID-19 and required intensive care. All of the patients were discharged between February 12 and April 10 2020, and the study follow-up took place in March of 2021.

Overall, 45 percent of the patients reported at least one symptom in that one-year follow-up. The most common symptoms were fatigue, sweating, chest tightness, anxiety, and myalgia (muscle pain). Having a severe case of COVID-19 increased the likelihood of long-lingering symptoms; 54 percent of the 680 severe cases reported at least one symptom after a year. But persistent symptoms were also common among the nonsevere cases, with 41.5 percent of 1,752 nonsevere cases reporting at least one symptom a year later.